A Clinical and Biochemical Study of Monoamine Oxidase Inhibition in Depressed Patients

1961 ◽  
Vol 107 (447) ◽  
pp. 239-243 ◽  
Author(s):  
W. G. Dewhurst ◽  
C. M. B. Pare
Keyword(s):  
Monoamine Oxidase ◽  
Clinical Application ◽  
Biochemical Study ◽  
Toxic Effects ◽  
Mao Inhibitors ◽  
Monoamine Oxidase Inhibition ◽  
Depressed Patients ◽  
Depressant Action ◽  
Oxidase Inhibition ◽  
Enzyme Monoamine Oxidase

The discovery that iproniazid benefits certain subjects with depression, linked with the demonstration that it inhibits the enzyme monoamine oxidase (MAO), led to the hypothesis that inhibition of MAO was the essential mechanism by which iproniazid caused relief of symptoms (Pletscher, 1959). Iproniazid, unfortunately, can produce serious toxic effects, particularly on the liver (Pare and Sandler, 1959), and this has limited its clinical application. For this reason a search has been made for MAO inhibitors with an effective anti-depressant action yet without the serious toxic effects of iproniazid. Among the newer compounds for which such claims have been made is N-isonicotinoyl (-N-N-benzylcarboxamidoethyl) hydrazine or Nialamide.

A Clinical and Biochemical Study of Monoamine Oxidase Inhibition in Depressed Patients

1961 ◽  
Vol 107 (447) ◽  
pp. 244-249 ◽  
Author(s):  
W. G. Dewhurst ◽  
C. M. B. Pare
Keyword(s):  
Monoamine Oxidase ◽  
Human Subject ◽  
Biochemical Study ◽  
Loading Dose ◽  
Monoamine Oxidase Inhibition ◽  
Enzyme Substrate ◽  
Before And After ◽  
Hydroxyindoleacetic Acid ◽  
Oxidase Inhibition ◽  
The Subject

In order to test whether a drug is an inhibitor of monoamine oxidase in the human subject, three main measures are available:1. We can measure an increased excretion of the normal substrates of the enzyme, e.g. tryptamine (Sjoerdsma, et al., 1959b).2. We can measure a decreased excretion of the metabolites resulting from the enzyme's action, e.g. 5-hydroxyindoleacetic acid (5-HIAA).3. We can administer a loading dose of an enzyme substrate and observe how the subject deals with it before and after the drug, e.g. 5-hydroxytryptamine (Sjoerdsma et al., 1958), and epinephrine (N-methyl-C14) (Resnick et al., 1958).

Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline

1989 ◽  
Vol 46 (5) ◽  
pp. 528-536 ◽  
Author(s):  
Rainer Schulz ◽  
Karl-Heinz Antonin ◽  
Edgar Hoffmann ◽  
Maria Jedrychowski ◽  
Eric Nilsson ◽  
...  
Keyword(s):  
Monoamine Oxidase ◽  
Monoamine Oxidase Inhibition ◽  
Oxidase Inhibition

scholarly journals Glycaemic control by monoamine oxidase inhibition in a patient with type 1 diabetes

2016 ◽  
Vol 14 (2) ◽  
pp. 163-165 ◽  
Author(s):  
Hamlin Emory ◽  
Neptune Mizrahi
Keyword(s):  
Type 1 Diabetes ◽  
Glycaemic Control ◽  
Monoamine Oxidase ◽  
Monoamine Oxidase Inhibitor ◽  
Combined Treatment ◽  
Insulin Regimen ◽  
Imaging Data ◽  
Monoamine Oxidase Inhibition ◽  
Oxidase Inhibition

We present clinical, electroencephalographic and low-resolution electromagnetic tomography data that support combined treatment with insulin and a monoamine oxidase inhibitor in a patient with type 1 diabetes. We suggest that brain imaging data can identify a subgroup of patients who are likely to benefit from an insulin regimen and monoamine oxidase inhibition to improve glycaemic control, cardiovascular function, normalize the circadian rhythm and restore perception of glycaemic awareness.

scholarly journals 3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells

2016 ◽  
Vol 41 (9) ◽  
pp. 2173-2178 ◽  
Author(s):  
David S. Goldstein ◽  
Yunden Jinsmaa ◽  
Patti Sullivan ◽  
Courtney Holmes ◽  
Irwin J. Kopin ◽  
...  
Keyword(s):  
Monoamine Oxidase ◽  
Pc12 Cells ◽  
Monoamine Oxidase Inhibition ◽  
Oxidase Inhibition ◽  
Spontaneous Oxidation
Sign in / Sign up

Export Citation Format

Share Document